why not try reading stuff that's out there, like this
https://www.fdanews.com/articles/208909-fda-declines-traveres-second-attempt-at-accelerated-approval-for-sparsentan
and this
https://ir.travere.com/news-releases/news-release-details/travere-completes-successful-pre-nda-meeting-filspari-igan
#trevere completed the largest ever phase3 trialy in fsg called "duplex". better phase2 data than the dimx asset
#excellent statistically significant interim result on proteinuria in phase3. FDA still said no to accelerated. Twice.
#the reasoning is laid bare. only a complete fool with head buried in sand thinks none of this is relevant
#what's so special about the dimx asset that make you think FDA will give them free pass to accelerated? I just don't see it. other ccr2 inhibitor from CSL failed in its fsg trial, no better than placebo
https://newsroom.csl.com/2020-05-18-VFMCRP-Press-Release-Phase-ii-Lumina-1-Trial-of-Ccx140
#question if this method of action is that effective in fsg disease but we'll know for certain once dimx phase3 finishes in few years
- Forums
- ASX - By Stock
- DXB
- Ann: ACTION3 IND Approved in China
Ann: ACTION3 IND Approved in China, page-145
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $214.4M |
Open | High | Low | Value | Volume |
39.0¢ | 39.0¢ | 37.0¢ | $503.5K | 1.322M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 26318 | 38.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.0¢ | 170072 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1318 | 0.380 |
3 | 72579 | 0.375 |
4 | 134161 | 0.370 |
1 | 30000 | 0.365 |
4 | 27499 | 0.360 |
Price($) | Vol. | No. |
---|---|---|
0.390 | 140963 | 5 |
0.395 | 61740 | 2 |
0.400 | 115000 | 2 |
0.405 | 86528 | 4 |
0.410 | 56400 | 2 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |